Pavmed offers warrants at half-price to raise cash for carpal tunnel syndrome device

Pavmed (NSDQ:PAVM) said this week that it plans to temporarily cut the exercise price of its outstanding Series W warrants in half. Each of the New York-based company’s outstanding warrants is currently exercisable at $5.00 apiece for one share of common stock. After Pavmed files tender offer materials, each warrant will have an exercise price of $2.50 per share. The company said it expects the offer will be good for 20 business days, but it could decide to extend the deal. “Pavmed is providing this opportunity to exercise warrants at a reduced price in order to encourage holders to exercise a meaningful portion of the outstanding warrants, providing the company with additional capital to advance its lead products, particularly its CarpX minimally invasive carpal tunnel syndrome device, through important near-term regulatory and commercialization milestones,” the company said in a statement. The CarpX percutaneous device helps doctors relieve compression of the median nerve without the need for a surgical incision. The product, positioned using ultrasound guidance, combines a balloon catheter with bipolar radio-frequency cutting electrodes. Pavmed filed a 510(k) application with the FDA for its CarpX device last month. The post Pavmed offers warrants at half-price to raise cash for carpal tunnel syndrome device appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Funding Roundup Pain Management Wall Street Beat Pavmed Source Type: news

Related Links:

Abstract Objective: Vasculogenic mimicry (VM) is a novel mechanism of tumor blood supply distinct from endothelial vessel (EV). VM is associated with malignancy, invasion, metastasis, and poor prognosis. Hitherto a noninvasive method for the assessment of VM in vivo has been lacking. Methods: Contrast-enhanced ultrasound (CEUS) was performed to evaluate the quantitative parameters of tumors in mice. CD31 immunohistochemistry-Periodic Acid-Schiff double staining was conducted to identify the VM or EV in tumor tissues. Correlations between perfusion parameters and VM density was analyzed by Pearson correlation ...
Source: Biological Procedures Online - Category: Molecular Biology Authors: Tags: Biol Proced Online Source Type: research
Conclusions: MGCE is safe, convenient, and tolerable for evaluating the gastric cavity and small intestine in pediatric patients. MGCE can effectively diagnose pediatric patients with abdominal pain. PMID: 31205466 [PubMed]
Source: Gastroenterology Research and Practice - Category: Gastroenterology Tags: Gastroenterol Res Pract Source Type: research
ConclusionIs convenient to consider a medication induced AP in patients without clear causative agent, such as the VA case presented. An etiological diagnosis algorithm of exclusion is proposed, for an adequate therapeutic approach in medication induced PNH. Algorithm validation is required.
Source: International Journal of Surgery Case Reports - Category: Surgery Source Type: research
I received a call the other day from someone supposedly at the social security administration asking for medical records for one of my patients who filed for disability. What's particularly eye raising is that I had finished seeing this patient for the first time earlier that same day. I was informed that every state has a set fee that a medical practice can charge for sending medical records for disability determinations. Is that true? I have never heard of that before. What is a fair... charging for disability forms and medical records
Source: Student Doctor Network - Category: Universities & Medical Training Authors: Tags: Pain Medicine Source Type: forums
ConclusionThe hysteroscopic-assisted single site resection of a cesarean scar defect is a feasible method for the resection of CSD. The use of the robot makes the difficult surgical techniques required for this surgery easier and more accessible.
Source: Journal of Minimally Invasive Gynecology - Category: OBGYN Source Type: research
Publication date: Available online 17 June 2019Source: Brain, Behavior, and ImmunityAuthor(s): Roman Fischer, Tanja Padutsch, Valerie Bracchi-Ricard, Kayla L. Murphy, George.F. Martinez, Niky Delguercio, Nicholas Elmer, Maksim Sendetski, Ricarda Diem, Ulrich L.M. Eisel, Richard J. Smeyne, Roland E. Kontermann, Klaus Pfizenmaier, John R. BetheaAbstractTumor necrosis factor receptor 2 (TNFR2) is a transmembrane receptor that promotes immune modulation and tissue regeneration and is recognized as a potential therapeutic target for multiple sclerosis (MS). However, TNFR2 also contributes to T effector cell function and macroph...
Source: Brain, Behavior, and Immunity - Category: Neurology Source Type: research
CONCLUSIONS: Anatomical variations in depth and diameter as well as the collapsibility due to intrathoracic pressures changes represent common challenges that face clinicians during central venous catheterization of the axillary vein. A noteworthy increase in vessel size as patients transition from spontaneous to mechanical ventilation may theoretically improve first-pass cannulation success with practitioners skilled in both ultrasound and procedure. As a result, placing a centrally inserted central catheter after the induction of anesthesia may be beneficial. PMID: 31204560 [PubMed - as supplied by publisher]
Source: The Journal of Vascular Access - Category: Surgery Tags: J Vasc Access Source Type: research
CONCLUSION: Caudocranial trajectory of the biopsy needle using a probe needle guide is as safe as the craniocaudal approach. Both approaches have similar yield and complications; however, the caudocranial approach provides ease to the patient during the procedure. PMID: 31204556 [PubMed - as supplied by publisher]
Source: The Journal of Vascular Access - Category: Surgery Tags: J Vasc Access Source Type: research
The FDA group reviewing the 510(k) application for Pavmed‘s (NSDQ:PAVM) CarpX device wants the company to resubmit the application. The FDA told the company that it had not reached a consensus within the review period set by the agency’s rules. To extend the review process, the FDA recommended that Pavmed resubmit the application. In a filing with the SEC, Pavmed said it initiated the submission this week and hopes to land a pre-submission meeting in the next 45 days. The company’s minimally-invasive CarpX device is designed to treat carpal tunnel syndrome. The device enables a physician to relieve c...
Source: Mass Device - Category: Medical Devices Authors: Tags: 510(k) Food & Drug Administration (FDA) Pain Management Regulatory/Compliance Pavmed Source Type: news
Within 24 hours of her second daughter’s birth, Dyane Harwood felt elated. From the moment she came home from the hospital, she started writing. Furiously. She wrote while nursing her daughter and going to the bathroom. She wrote on her hands, on the bathroom mirror, inside books and on tabletops. She yearned to write down every thought she was having. She wrote so much that her wrists ached—her carpal tunnel returning—and she was in constant pain. She also had endless energy and a newfound enthusiasm for life. She felt like she could run a long race. She couldn’t sit still, and her speech was fast ...
Source: World of Psychology - Category: Psychiatry & Psychology Authors: Tags: Bipolar Disorders General Health-related Mental Health and Wellness Self-Help Sleep Women's Issues Johns mood disorder Motherhood Parenting postpartum bipolar disorder postpartum depression Postpartum Disorder Source Type: blogs
More News: Bipolar | Carpal Tunnel Syndrome | Funding | Mania | Medical Devices | Pain | Pain Management | Sports Medicine | Ultrasound